Nanoscope Therapeutics Inc. Email Format

Biotechnology ResearchTexas, United States11-50 Employees

Nanoscope Therapeutics is a Dallas-based biotechnology company developing optogenetic therapies intended to restore vision for patients with retinal degenerative diseases. Its approach is disease-agnostic and designed as a one-time, in-office injection that does not require genetic testing; the lead program, MCO-010, has progressed from a Phase 2b trial in retinitis pigmentosa toward a rolling FDA submission, with encouraging results from a Phase 2 trial in Stargardt disease.

The company targets patients experiencing photoreceptor loss and vision impairment from retinal degeneration, with plans to address additional conditions such as geographic atrophy and Leber congenital amaurosis. It operates in the biotechnology research sector and aims to establish U.S. commercialization and access pathways, including partnerships to support clinicians and patients. In May 2026, it announced that InspiroGene by McKesson will provide U.S. commercialization services for its lead product, subject to regulatory approval.

Get verified Nanoscope Therapeutics Inc. emails free

Company overview Employee directory